For patients with metastatic NSCLC without driver mutation of EGFR, ALK, and ROS1, drugs that act on the PD-1/PDL-1 axis are predominantly used in the first-line setting with or without platinum chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.